Pre-earnings brief
Reports
Thu, Jul 30, 2026
Est. EPS
—
Est. revenue
—
Implied move
±0.2%
EPS beat rate
75%
Why consensus could be wrong
The Street may be underestimating Apellis's ability to deliver strong EPS results, as evidenced by their recent performance and the lack of revenue guidance may be overly cautious.
Supporting evidence
The company has a 75% EPS beat rate over the last eight quarters, indicating a strong track record of exceeding expectations.
Despite recent volatility, the stock has shown resilience in the face of earnings surprises.
Key risk
If the EPS comes in above $0.20, it could challenge the cautious sentiment currently held by the market.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around Apellis's ability to maintain profitability while navigating market challenges.
Bull confirmed if
An EPS of $0.20 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $0.10 would confirm the bear case, raising concerns about the company's profitability.
What the market is pricing for the move.
Implied Move
±0.24%
Historical Avg
±8.8%
The options market is pricing a very modest move in the stock, suggesting that investors are not anticipating significant volatility around the earnings report.
Options are pricing ±0.2% while APLS has averaged ±8.8% over the last 8 prints — setup is pricing cheap.
30d HV
2.6%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options pricing cheap in Health Care
Fade rate: 11 of 30 (37%)
This setup has occurred 30 times across Health Care in the last 2 years. 19 of 30 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 3.7%, with a raw directional average of -0.1% (roughly flat historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Apellis beats expectations, history suggests the stock could see a modest decline of around 4.6% on the first day, but this could confirm a strong operational outlook.
In line / cautious
If results are in line with expectations, the stock may react cautiously, potentially leading to a flat or slightly negative movement as investors digest the details.
Miss
If the company misses expectations, history suggests a potential decline of around 3.8%, reflecting investor disappointment.
The lines on the call that would change the story.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±7.0%
Apellis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases. Operating in the health care sector, Apellis is particularly noted for its work in complement inhibition, which targets the immune system to treat conditions like geographic atrophy associated with age-related macular degeneration.
Last quarter
In Q1-2026, Apellis reported an EPS of $0.15, significantly beating analyst expectations of a loss of $0.38. Despite this positive surprise, the stock fell slightly the next day, indicating mixed investor sentiment.
EPS beat streak
4Q
EPS beat rate
75%
Avg EPS surprise
+40.64%
Avg 1-day reaction
-4.40%
Overall expectations for Apellis are cautiously optimistic, given their recent earnings surprises. However, the lack of revenue guidance may lead to uncertainty among investors.
Bull case
If Apellis continues to deliver strong EPS results and demonstrates solid revenue growth, it could bolster investor confidence and drive the stock price higher.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the recent volatility.
Key metrics to watch
Earnings Per Share (EPS)
$0.15EPS is a crucial indicator of the company's profitability and financial health, which investors will closely monitor.
Revenue Growth
N/ARevenue growth reflects the company's ability to expand its market presence and increase sales, which is vital for sustaining long-term growth.
The print will turn on these.
Q1
What will be the actual EPS reported for Q2-2026?
Given the company's recent history of beating EPS estimates, the actual figure will be critical in determining investor sentiment and stock movement.
Q2
Will there be any guidance on revenue for the upcoming quarters?
Revenue guidance is essential for assessing the company's growth trajectory and could significantly impact stock performance.
Market Reaction to Earnings Surprise
N/AUnderstanding how the stock has reacted to past earnings surprises can provide insight into potential volatility following the upcoming report.